Daily Archives: August 25, 2020
Vaccines targeting SARS-CoV-2 tested in humans
25 Aug, 2020 | 03:56h | UTCVaccines targeting SARS-CoV-2 tested in humans – Nature Medicine
Commentary on Twitter
No #SARSCoV2 vaccine has yet to be shown to be effective or safe.
Effective = it prevents infections.
Safe = it doesn't engender serious adverse effects.https://t.co/dsyk8m6pEx@NatureMedicine
Please keep this in mind now that @US_FDA's @SteveFDA has lost all credibility pic.twitter.com/OgQIpDPv6R— Eric Topol (@EricTopol) August 24, 2020
First Covid-19 reinfection documented in Hong Kong
25 Aug, 2020 | 04:00h | UTCFirst Covid-19 reinfection documented in Hong Kong, researchers say – STAT
Commentaries: Some people can get the pandemic virus twice, a study suggests. That is no reason to panic – Science AND You can get reinfected with Covid-19 but still have immunity. Let’s explain – Vox AND Expert reaction to first reported case of COVID-19 re-infection in Hong Kong patient – Science Media Centre
Commentary on Twitter
In Hong Kong, researchers reported what appears to be the first confirmed case of Covid-19 reinfection in a 33-year-old man. The virus sequenced from his two infections didn't match, indicating the second one was not tied to the first. https://t.co/4GHd1lMRZ0
— STAT (@statnews) August 24, 2020
FDA issues emergency use authorization for convalescent plasma as potential COVID–19 treatment
25 Aug, 2020 | 03:58h | UTCCommentaries: Convalescent Plasma: The Science and the Politics – Science Translational Medicine AND Convalescent plasma: another controversial clash of politics & science – Health News Review AND Observational Study of Convalescent Plasma and FDA Response – datamethods AND FDA OKs use of convalescent plasma for COVID-1 – CIDRAP AND Is convalescent plasma safe and effective? We answer the major questions about the Covid-19 treatment – STAT
Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19
25 Aug, 2020 | 03:53h | UTC
An inflammatory cytokine signature predicts COVID-19 severity and survival
25 Aug, 2020 | 03:57h | UTCAn inflammatory cytokine signature predicts COVID-19 severity and survival – Nature
Commentary: Researchers discover immune predictors of COVID-19 cases that fare the worst – The Mount Sinai Hospital
Commentary on Twitter
Elevated levels of serum IL-6 and TNF-α at the time of hospitalization are independent and significant predictors of clinical outcome in two cohorts of patients with #COVID19 #biomarker @IcahnMountSinai @SinaiImmunol @TischCancer @MiriamMerad https://t.co/syHWT6QaW0
— Nature Medicine (@NatureMedicine) August 24, 2020
Not just antibodies: B cells and T cells mediate immunity to COVID-19
25 Aug, 2020 | 03:54h | UTCNot just antibodies: B cells and T cells mediate immunity to COVID-19 – Nature Reviews Immunology
Commentary on Twitter
Concise and useful summary of the B and T cell response to #COVID19https://t.co/RQ2ABn8CYf@NatRevImmunol pic.twitter.com/Bk9IiJFfwQ
— Eric Topol (@EricTopol) August 24, 2020
Cost of contact: Redesigning healthcare in the age of COVID
25 Aug, 2020 | 03:51h | UTCCost of contact: redesigning healthcare in the age of COVID – BMJ Quality & Safety
Commentary on Twitter
The ‘cost of contact’ associated with risks of COVID-19 is forcing redesign of healthcare. That may be a good thing. say @sacha_bhatia, @kgshojania and Wendy Levinson, but it needs to be done well. https://t.co/cq5gYtuvMT
— BMJ Quality & Safety (@BMJ_Qual_Saf) August 24, 2020
Building a better health care system post-Covid-19: Steps for reducing low-value and wasteful care
25 Aug, 2020 | 03:52h | UTC
The disappearance of the primary care physical examination—losing touch
25 Aug, 2020 | 03:49h | UTCThe Disappearance of the Primary Care Physical Examination—Losing Touch – JAMA Internal Medicine (free for a limited period)
Face masks: Benefits and risks during the COVID-19 crisis
25 Aug, 2020 | 03:43h | UTCFace masks: benefits and risks during the COVID-19 crisis – European Journal of Medical Research
WHO: 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility
25 Aug, 2020 | 03:48h | UTC
Commentary on Twitter
Urgent, broadscale commitment & investment from countries is?to achieve the goal of COVAX to bring the pandemic under control by accelerating the development & manufacture of #COVID19 vaccines, & to guarantee fair & equitable access for all countries?
?https://t.co/CPNzyTjsLz pic.twitter.com/jBupCY7dur
— World Health Organization (WHO) (@WHO) August 24, 2020
The unequal scramble for coronavirus vaccines — by the numbers
25 Aug, 2020 | 03:47h | UTCThe unequal scramble for coronavirus vaccines — by the numbers – Nature
Meta-analysis: Efficacy and safety of gastrointestinal bleeding prophylaxis in critically ill patients
25 Aug, 2020 | 03:40h | UTC
Podcast: Hypertension in the Hospital
25 Aug, 2020 | 03:38h | UTCAnnals On Call – Hypertension in the Hospital – Annals of Internal Medicine
Commentary on Twitter
Listen to the latest #AnnalsOnCall with @medrants, Dr Timothy Anderson, and @WrayCharles on #Hypertension in the Hospital https://t.co/OouHuYg0wt. pic.twitter.com/CbJyq7wyDq
— Annals of Int Med (@AnnalsofIM) August 24, 2020
Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients
25 Aug, 2020 | 03:45h | UTC
Observational study: Revascularization practices and outcomes in patients with multivessel coronary artery disease who presented with acute myocardial infarction and cardiogenic shock
25 Aug, 2020 | 03:42h | UTCRevascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018 – JAMA Internal Medicine (free for a limited period)
Editorial: Multivessel or Culprit Vessel–Only Percutaneous Coronary Intervention for Patients With Acute Myocardial Infarction and Cardiogenic Shock: Real-World Evidence in Support of CULPRIT-SHOCK (free for a limited period)
Commentaries: Multivessel PCI Associated With Higher In-Hospital Mortality Compared With Culprit-Vessel PCI, NCDR Study Finds – American College of Cardiology AND Less aggressive treatment better for heart patients who go into shock – Yale University
Related Research: PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock – New England Journal of Medicine AND One-Year Outcomes after PCI Strategies in Cardiogenic Shock – New England Journal of Medicine
Commentary on Twitter (Thread – Click for more)
In @JAMAInternalMed is our evaluation of revascularization practices in AMI w shock
In 2017, CULPRIT-SHOCK found harm w MV-PCI in MV-CAD – in the decade preceding it, MV-PCI was an increasingly popular strategy.
?below
w/ @rwyeh @ACCinTouch https://t.co/xz0HHnvhNU pic.twitter.com/DWaVXG8vcU
— Rohan Khera (@rohan_khera) August 24, 2020
The neuroleptic malignant syndrome—a systematic case series analysis focusing on therapy regimes and outcome
25 Aug, 2020 | 03:37h | UTCCommentary: Treating Neuroleptic Malignant Syndrome: A Case Series – NEJM Journal Watch